Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases

<p>Read sequencing depth by sample</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	N. Ari Wijetunga (15056183) (author)
Drugi avtorji:	Alexander G. Goglia (15056186) (author), Nils Weinhold (15056189) (author), Michael F. Berger (15048171) (author), Michael Cislo (15056192) (author), Daniel S. Higginson (14949837) (author), Kiana Chabot (15056195) (author), Ahmed M. Osman (15056198) (author), Lauren Schaff (15056201) (author), Elena Pentsova (15056204) (author), Alexandra M. Miller (15056207) (author), Simon N. Powell (15056210) (author), Adrienne Boire (14944705) (author), Jonathan T. Yang (15056213) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Methods and Technology CNS Cancers Gene Technologies High-throughput sequencing Liquid Biopsy Radiation Oncology Molecular targets of radiation response Translational Research
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
od: N. Ari Wijetunga (15056183)
Izdano: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
od: N. Ari Wijetunga (15056183)
Izdano: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
od: N. Ari Wijetunga (15056183)
Izdano: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Izdano: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Izdano: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
od: Francesca Orzan (15055579)
Izdano: (2025)

Supplementary Figure S1 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
od: Rumani Singh (17141575)
Izdano: (2025)

Supplementary Figure S2 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
od: Rumani Singh (17141575)
Izdano: (2025)

Supplementary Figure S3 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
od: Rumani Singh (17141575)
Izdano: (2025)

Supplementary Figure S4 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
od: Rumani Singh (17141575)
Izdano: (2025)

Supplementary Figure S5 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
od: Rumani Singh (17141575)
Izdano: (2025)

Supplementary Figure S6 from Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX
od: Rumani Singh (17141575)
Izdano: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Izdano: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Izdano: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Izdano: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Izdano: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
od: Mengjie Zhao (14845174)
Izdano: (2025)

Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
od: Amy C. Degnim (15106462)
Izdano: (2025)

Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
od: Amy C. Degnim (15106462)
Izdano: (2025)

Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
od: Amy C. Degnim (15106462)
Izdano: (2025)

Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
od: Bouchra Tawk (15389486)
Izdano: (2025)

Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Immunohistochemical staining for PHLDA3, APOE, and CPE in irradiated brain tissues.
od: Jing Liu (38537)
Izdano: (2025)

Supplementary Table 1 from Monounsaturated and Diunsaturated Fatty Acids Sensitize Cervical Cancer to Radiation Therapy
od: Naoshad Muhammad (14960127)
Izdano: (2025)

Supplementary Table 2 from Monounsaturated and Diunsaturated Fatty Acids Sensitize Cervical Cancer to Radiation Therapy
od: Naoshad Muhammad (14960127)
Izdano: (2025)

Global Wildfire Brown Carbon Simulation Results: Supporting Data for "Strong Shortwave Absorption by Wildfire Brown Carbon from Global Observations and Modeling"
od: Lulu Xu (21634004)
Izdano: (2025)

2024 Meteorological Data, Upper Chesapeake Bay, MarineGEO, Smithsonian Environmental Research Center
od: Sam Benson (17684957)
Izdano: (2025)

Supplementary Figure 1 from Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer
od: Michelle L. Mierzwa (14963463)
Izdano: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
od: Sami Belhadj (15052341)
Izdano: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
od: Cloud P. Paweletz (14960112)
Izdano: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
od: Whitney L. Hensing (16461978)
Izdano: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
od: Stephanie Lheureux (16797697)
Izdano: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
od: Stephanie Lheureux (16797697)
Izdano: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
od: Stephanie Lheureux (16797697)
Izdano: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
od: Stephanie Lheureux (16797697)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4o6tf5cnrct65c7qn2sornpg39